Literature DB >> 8111073

A charge selectivity impairment in protein permselectivity is present in type 2 diabetes.

S Morano1, P Pietravalle, M G De Rossi, G Mariani, G Cristina, F Medici, M Sensi, D Andreani, U Di Mario.   

Abstract

A possible loss in kidney charge permselectivity of proteins before any manifestation of nephropathy has been sought in type 2 (non-insulin-dependent) diabetes by assessing the clearances of proteins differing in charge and/or size (anionic and cationic immunoglobulins, albumin). Eighty-five consecutive outpatients with type 2 diabetes were studied and compared with 101 normal subjects. Of the patients, 14.1% were microalbuminuric and 2.3% macroalbuminuric. A significant increase in protein clearances was observed in diabetic patients in comparison with normal subjects: the median of albumin clearance was 0.09 ml/min, interquartile range (IR) 0.04-0.31 (P < 0.01 vs normals); that of anionic immunoglobulins (IgG4) 0.02 ml/min, IR 0.04-0.05 (P < 0.005 vs normals); and that of neutral/cationic immunoglobulins (IgG) 0.13 ml/min, IR 0.07-0.19 (P < 0.01 vs normals). The anionic/cationic immunoglobulin ratio median was 0.22, IR 0.11-0.43, and exceeded the upper limit of normal values in 29.4% of all patients. IgG4 clearance was positively correlated with albumin clearance (r = 0.72) and with IgG clearance (r = 0.98). Nevertheless anionic immunoglobulin clearance was increased in a number of patients (17.3%) with normal IgG excretion and even in patients (15.1%) with normal albumin clearance. Clearances of IgG4 and IgG, but not that of albumin, were correlated with the duration of diabetes. Thus, an increased anionic/cationic IgG ratio in type 2 diabetes highlights a charge selectivity defect in protein permselectivity; this selective proteinuria may reflect more accurately than does microalbuminuria an early kidney abnormality in this form of diabetes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8111073     DOI: 10.1007/bf00572857

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  24 in total

1.  New parameters to monitor the progression of diabetic nephropathy.

Authors:  U Di Mario; S Morano; A Cancelli; S Bacci; S Frontoni; P Pietravalle; S Gambardella; D Andreani
Journal:  Am J Kidney Dis       Date:  1989-01       Impact factor: 8.860

2.  Glomerular size and charge selectivity in insulin-dependent diabetes mellitus.

Authors:  T Deckert; B Feldt-Rasmussen; R Djurup; M Deckert
Journal:  Kidney Int       Date:  1988-01       Impact factor: 10.612

Review 3.  Albuminuria reflects widespread vascular damage. The Steno hypothesis.

Authors:  T Deckert; B Feldt-Rasmussen; K Borch-Johnsen; T Jensen; A Kofoed-Enevoldsen
Journal:  Diabetologia       Date:  1989-04       Impact factor: 10.122

4.  Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes.

Authors:  C E Mogensen
Journal:  N Engl J Med       Date:  1984-02-09       Impact factor: 91.245

5.  Charge selectivity of proteinuria in type I diabetes explored by Ig subclass clearance.

Authors:  P Pietravalle; S Morano; G Cristina; M G De Rossi; G Mariani; P Cotroneo; G Ghirlanda; A Clementi; D Andreani; U Di Mario
Journal:  Diabetes       Date:  1991-12       Impact factor: 9.461

6.  Charge selectivity of proteinuria in diabetic glomerulopathy.

Authors:  Y Nakamura; B D Myers
Journal:  Diabetes       Date:  1988-09       Impact factor: 9.461

7.  Urinary albumin excretion in patients with non-insulin-dependent diabetes mellitus in an early microalbuminuric stage.

Authors:  O Hotta; Y Taguma; M Mitsuoka; K Takeshita; H Takahashi
Journal:  Nephron       Date:  1991       Impact factor: 2.847

8.  Heparan sulfate proteoglycan in the glomerular basement membrane in type 1 diabetes mellitus.

Authors:  R L Vernier; M W Steffes; S Sisson-Ross; S M Mauer
Journal:  Kidney Int       Date:  1992-04       Impact factor: 10.612

9.  Improved metabolic control does not alter the charge-dependent glomerular filtration of albumin in uncomplicated type 1 (insulin-dependent) diabetes.

Authors:  A Kverneland; B Welinder; B Feldt-Rasmussen; T Deckert
Journal:  Diabetologia       Date:  1988-09       Impact factor: 10.122

10.  Glomerular proteoglycans in diabetes. Partial structural characterization and metabolism of de novo synthesized heparan-35SO4 and dermatan-35SO4 proteoglycans in streptozocin-induced diabetic rats.

Authors:  D J Klein; D M Brown; T R Oegema
Journal:  Diabetes       Date:  1986-10       Impact factor: 9.461

View more
  4 in total

Review 1.  The glomerular basement membrane as a model system to study the bioactivity of heparan sulfate glycosaminoglycans.

Authors:  Kevin J McCarthy; Deborah J Wassenhove-McCarthy
Journal:  Microsc Microanal       Date:  2012-02       Impact factor: 4.127

2.  Urinary markers of glomerular injury in diabetic nephropathy.

Authors:  Abraham Cohen-Bucay; Gautham Viswanathan
Journal:  Int J Nephrol       Date:  2012-05-08

3.  Increased Urine IgM and IgG(2) Levels, Indicating Decreased Glomerular Size Selectivity, Are Not Affected by Dalteparin Therapy in Patients with Type 2 Diabetes.

Authors:  Ole Torffvit; Majid Kalani; Jan Apelqvist; Björn Eliasson; Jan W Eriksson; Kerstin Brismar; Gun Jörneskog
Journal:  Biochem Res Int       Date:  2012-02-12

4.  IgG subclass deposition in diabetic nephropathy.

Authors:  Xuanli Tang; Feng Wan; Qin Zhu; Tian Ye; Xue Jiang; Haichun Yang
Journal:  Eur J Med Res       Date:  2022-08-11       Impact factor: 4.981

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.